Atlas Arteria (MAQAF) Stock Price, News & Analysis

Company Overview

Atlas Arteria Group is an owner and manager of transportation infrastructure assets, with a focus on toll roads and related concessions. The company invests in, develops and operates long-term road infrastructure under public-private partnership and concession arrangements, generating revenue from toll collections and other transportation-related activities.

Atlas Arteria’s portfolio includes interests in the APRR and AREA motorway networks in France, which together form one of the country’s major tolled motorway systems. The company also owns the Dulles Greenway in Virginia, a privately operated toll road connecting the Washington, D.C., metropolitan area with Loudoun County, and the Warnow Tunnel in Rostock, Germany.

The business was established in 2005 as Macquarie Atlas Roads and adopted the Atlas Arteria name in 2018 following the internalization of its management structure. Atlas Arteria is headquartered in Australia and is listed on the Australian Securities Exchange. Its leadership has included Managing Director and Chief Executive Officer Graeme Bevans and Chairman David Bartholomew.

Key Stats

• Today's Range: $2.64 to $2.64
• 50-Day Range: $2.64 to $3.68
• 52-Week Range: $2.64 to $4.09
• Volume: N/A
• Average Volume: 1,203 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 3.14%
• Price Target: $5.03
• Consensus Rating: Hold

Atlas Arteria Stock Analysis - MarketRank™

Atlas Arteria scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Atlas Arteria has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Atlas Arteria has a consensus price target of $5.03, representing about 90.5% upside from its current price of $2.64.

Amount of Analyst Coverage

Atlas Arteria has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Atlas Arteria is -25.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atlas Arteria is -25.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Atlas Arteria has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Atlas Arteria has recently decreased by 20.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Atlas Arteria is a leading dividend payer. It pays a dividend yield of 5.02%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Atlas Arteria does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Atlas Arteria this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atlas Arteria insiders have not sold or bought any company stock.

Percentage Held by Institutions

24.06% of the stock of Atlas Arteria is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Industrials
• Industry: Infrastructure Operations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MAQAF
• CIK: N/A
• Web: www.atlasarteria.com
• Phone: 611800621694
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Atlas Arteria: $5.03
• High Price Target: $5.31
• Low Price Target: $4.75
• Potential Upside/Downside: +90.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A